

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/495, 31/445, C07D 401/04, 403/04		A1	(11) International Publication Number: WO 96/31214 (43) International Publication Date: 10 October 1996 (10.10.96)
(21) International Application Number: PCT/US96/04571		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 April 1996 (03.04.96)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 08/418,994 6 April 1995 (06.04.95) US			
(71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).			
(72) Inventors: CHO, Sung-Yong, S.; 2889 Greer Road, Palo Alto, CA 94303 (US). HIPS KIND, Philip, A.; 3660 South Farmstone Circle, New Palestine, IN 46163 (US). HOWBERT, James, Jeffry; 12740 Northeast 30th Street, Bellevue, WA 98005 (US). MUEHL, Brian, S.; 940 Country Lane, Indianapolis, IN 46217 (US). NIXON, James, A.; 7375 Taos Trail, Indianapolis, IN 46219 (US).			
(74) Agents: GAYLO, Paul, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).			
(54) Title: 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS			
(57) Abstract <p>This invention provides a series of novel substituted propanamides which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NZ	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

2-ACYLAminOPROpanAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS

5 Tachykinins are a family of peptides which share a common amidated carboxy terminal sequence. Substance P was the first peptide of this family to be isolated, although its purification and the determination of its primary sequence did not occur until the early 1970's.

10 Between 1983 and 1984 several groups reported the isolation of two novel mammalian tachykinins, now termed neurokinin A (also known as substance K, neuromedin L, and neurokinin α), and neurokinin B (also known as neuromedin K and neurokinin β). See, J.E. Maggio, Peptides, 6 (Supplement 3):237-243 (1985) for a review of these discoveries.

15 Tachykinins are widely distributed in both the central and peripheral nervous systems, are released from nerves, and exert a variety of biological actions, which, in most cases, depend upon activation of specific receptors expressed on the membrane of target cells. Tachykinins are also produced by a number of non-neuronal tissues.

20 The mammalian tachykinins substance P, neurokinin A, and neurokinin B act through three major receptor subtypes, denoted as NK-1, NK-2, and NK-3, respectively. These receptors are present in a variety of organs.

25 Substance P is believed inter alia to be involved in the neurotransmission of pain sensations, including the pain associated with migraine headaches and with arthritis. These peptides have also been implicated in gastrointestinal disorders and diseases of the gastrointestinal tract such as inflammatory bowel disease. Tachykinins 30 have also been implicated as playing a role in numerous other maladies, as discussed infra.

Tachykinins play a major role in mediating the sensation and transmission of pain or nociception, especially migraine headaches. see, e.g., S.L. Shepheard, et al., British Journal of Pharmacology, 108:11-20 (1993); S.M. Moussaoui, et al., European

- 2 -

Journal of Pharmacology, 238:421-424 (1993); and W.S. Lee, et al., British Journal of Pharmacology, 112:920-924 (1994).

In view of the wide number of clinical maladies associated with an excess of tachykinins, the development of tachykinin receptor antagonists will serve to control these clinical conditions. The earliest tachykinin receptor antagonists were peptide derivatives. These antagonists proved to be of limited pharmaceutical utility because of their metabolic instability.

Recent publications have described novel classes of non-peptidyl tachykinin receptor antagonists which generally have greater oral bioavailability and metabolic stability than the earlier classes of tachykinin receptor antagonists. Examples of such newer non-peptidyl tachykinin receptor antagonists are found in United States Patent 5,491,140, issued February 13, 1996; United States Patent 5,328,927, 10 issued July 12, 1994; United States Patent 5,360,820, issued November 1, 1994; United States Patent 5,344,830, issued September 6, 1994; United States Patent 5,331,089, issued July 19, 1994; European Patent Publication 591,040 A1, published April 6, 1994; Patent Cooperation Treaty publication WO 94/01402, published January 20, 1994; Patent 15 Cooperation Treaty publication WO 94/04494, published March 3, 1994; Patent Cooperation Treaty publication WO 93/011609, published January 21, 1993; Canadian Patent Application 2154116, published January 23, 1996; European Patent Publication 693,489, published January 24, 1996; and Canadian Patent Application 2151116, published December 11, 1995.

20 In essence, this invention provides a class of potent non-peptide tachykinin receptor antagonists. By virtue of their non-peptide nature, the compounds of the present invention do not suffer from the shortcomings, in terms of metabolic instability, of known peptide-based tachykinin receptor antagonists.

25 As noted in Patent Cooperation Treaty published application WO 93/01169, published January 21, 1993, compounds similar to those of the present invention have been described in various sources.

30 Inhibition of benzodiazepine receptor binding in vitro by benzyl (3-(3-indolyl)-2-aminopropionate is disclosed in Biochemical Pharmacology, 30:3016-3019 (1981). Arzneim-Forsch, 32(I):684-685 (1982)

- 3 -

reports that benzyl (2-(3-indolyl)-2-aminopropionate is an antisickling agent and an inhibitor of glucose transport in human erythrocytes in vitro. A weak inhibition of estrogen binding to rat alpha-fetoprotein by benzyl 3-(3-indolyl)-2-aminopropionate in vitro is disclosed in Journal of Steroid Biochemistry, 16:503-507 (1982).

5 Australian Journal of Chemistry, 28:2065-2068, discloses 4-nitrobenzyl 3-(3-indolyl)-2-aminopropionate, 4-nitrobenzyl 2-(1,1-dimethylethoxycarbonylamino)-3-(3-indolyl)propionate, and benzyl 2-(1,1-dimethylethoxycarbonylamino)-3-(3-indolyl)propionate. There is no
10 suggestion in this article that the disclosed compounds are useful in medicine.


10 Journal of Organic Chemistry, 42:1286-1290 (1977), discloses 4-methoxybenzyl 2-(1,1-dimethylethoxycarbonylamino)-3-(3-indolyl)propionate. No medical use is suggested.

15 Australian Journal of Chemistry, 31:1865-1868 (1978), discloses 2,4,6-trimethylbenzyl 3-(3-indolyl)-2-aminopropionate and 4-nitrobenzyl 3-phenyl-2-aminopropionate. There is no disclosure of a use in medicine.

20 There is no suggestion in any of these references of the compounds of the present invention nor their usefulness in treating or preventing conditions associated with an excess of tachykinins. Because of the current dissatisfaction of the currently marketed treatments for treating the conditions associated with an excess of tachykinins within the affected population, there exists a need for a more efficacious and
25 safe treatment.

30 This invention encompasses methods for the treatment or prevention of a physiological disorder associated with an excess of tachykinins, which method comprises administering to a mammal in need of said treatment an effective amount of a compound of Formula I

- 4 -



wherein:

5

R¹ is hydrogen, C₁-C₆ alkyl, or C₂-C₆ alkanoyl;

10

R², R³, R⁴, R⁵, and R⁶ are independently selected from the group consisting of hydrogen, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylamino, C₁-C₆ alkylthio, amino, and trifluoromethyl;

15

R^a and R^b are each hydrogen or together form an oxo group;

15


R^c and R^d are each hydrogen or together form an oxo group;

20

Z is a bond or C₁-C₆ alkylene; and

X is

- 5 -



N-R⁷, CH-NR⁸R⁹, or CH-R¹⁰

5 where R⁷, R⁸, R⁹, and R¹⁰ are independently selected
from the group consisting of hydrogen and C₁-C₆
alkyl;

10 or a pharmaceutically acceptable salt or solvate thereof.

15 In another embodiment, this invention provides the novel
compounds of Formula I and the salts or solvates thereof, as well as
pharmaceutical formulations comprising, as an active ingredient, a
compound of Formula I in combination with one or more
pharmaceutically acceptable carriers, diluents, or excipients.

20 The terms and abbreviations used in the instant examples
have their normal meanings unless otherwise designated. For example
“°C” refers to degrees Celsius; “N” refers to normal or normality;
“mmol” refers to millimole or millimoles; “g” refers to gram or grams;
25 “ml” means milliliter or milliliters; “M” refers to molar or molarity;
“MS” refers to mass spectrometry; “FDMS” refers to field desorption
mass spectrometry; “UV” refers to ultraviolet spectroscopy; “IR” refers
to infrared spectroscopy; and “NMR” refers to nuclear magnetic
resonance spectroscopy.

As used herein, the term “C₁-C₆ alkyl” refers to straight or
branched, monovalent, saturated aliphatic chains of 1 to 6 carbon atoms

- 6 -

and includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, pentyl, isopentyl, and hexyl. The term "C₁-C₆ alkyl" includes within its definition the term "C₁-C₄ alkyl".

5 "Halo" represents chloro, fluoro, bromo or iodo.

"C₁-C₆ alkylthio" represents a straight or branched alkyl chain having from one to six carbon atoms attached to a sulfur atom. Typical C₁-C₆ alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio and the like. The term "C₁-C₆ alkylthio" includes 10 within its definition the term "C₁-C₄ alkylthio".

15 "C₁-C₆ alkylamino" represents a straight or branched alkylamino chain having from one to six carbon atoms attached to an amino group. Typical C₁-C₆ alkyl-amino groups include methylamino, ethylamino, propylamino, isopropylamino, butylamino, *sec*-butylamino and the like.

20 "C₁-C₆ alkoxy" represents a straight or branched alkyl chain having from one to six carbon atoms attached to an oxygen atom. Typical C₁-C₆ alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, *t*-butoxy, pentoxy and the like. The term "C₁-C₆ alkoxy" includes within its definition the term "C₁-C₄ alkoxy".

25 "C₂-C₆ alkanoyl" represents a straight or branched alkyl chain having from one to five carbon atoms attached through a carbonyl moiety. Typical C₂-C₆ alkanoyl groups include ethanoyl (also referred to as acetyl), propanoyl, isopropanoyl, butanoyl, *t*-butanoyl, pentanoyl, hexanoyl, and the like.

30 "C₁-C₆ alkylene" refers to a straight or branched, divalent, saturated aliphatic chain of one to six carbon atoms and includes, but is not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, *t*-butylene, pentylene, isopentylene, hexylene, and the like.

35 The term "heterocycle" represents a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated or unsaturated and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of nitrogen, oxygen or sulfur, and wherein the nitrogen and sulfur heteroatoms may

optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized and including a bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which affords a 5 stable structure.

The term "amino-protecting group" as used in the specification refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups on the compound. Examples of such 10 amino-protecting groups include formyl, trityl, phthalimido, trichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl, and urethane-type blocking groups such as benzyloxycarbonyl, 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 15 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, *t*-butoxycarbonyl, 1,1-diphenyleth-1-yloxycarbonyl, 1,1-diphenylprop-1-yloxycarbonyl, 20 2-phenylprop-2-yloxycarbonyl, 2-(*p*-toluyl)-prop-2-yloxycarbonyl, cyclopentanyloxycarbonyl, 1-methylcyclopentanyloxycarbonyl, cyclohexanyloxycarbonyl, 1-methylcyclohexanyloxycarbonyl, 2-methylcyclohexanyloxycarbonyl, 2-(4-tolylsulfonyl)-ethoxycarbonyl, 2-(methylsulfonyl)ethoxycarbonyl, 25 2-(triphenylphosphino)-ethoxycarbonyl, fluorenylmethoxy-carbonyl ("FMOC"), 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl, 5-benzoisoxalylmethoxycarbonyl, 4-acetoxybenzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-ethynyl-2-propoxycarbonyl, 30 cyclopropylmethoxycarbonyl, 4-(decyloxy)benzyloxycarbonyl, isobornyloxycarbonyl, 1-piperidyloxycarbonyl and the like; benzoylmethylsulfonyl group, 2-nitrophenylsulfenyl, diphenylphosphine oxide and like amino-protecting groups. The species of amino-protecting group employed is usually not critical so long as the 35 derivatized amino group is stable to the condition of subsequent reactions on other positions of the intermediate molecule and can be


- 8 -

selectively removed at the appropriate point without disrupting the remainder of the molecule including any other amino-protecting groups. Preferred amino-protecting groups are trityl, *t*-butoxycarbonyl (*t*-BOC), allyloxycarbonyl and benzyloxycarbonyl. Further examples of 5 groups referred to by the above terms are described by E. Haslam, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY, (J.G.W. McOmie, ed., 1973), at Chapter 2; and T.W. Greene and P.G.M. Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (1991), at Chapter 7.

10 The term "leaving group" as used herein refers to a group of atoms that is displaced from a carbon atom by the attack of a nucleophile in a nucleophilic substitution reaction. The term "leaving group" as used in this document encompasses, but is not limited to, activating groups.

15 The term "activating group" as used herein refers a leaving group which, when taken with the carbonyl (-C=O) group to which it is attached, is more likely to take part in an acylation reaction than would be the case if the group were not present, as in the free acid. Such activating groups are well-known to those skilled in the art and may be, for example, succinimidoxy, phthalimidoxy, benzotriazolyloxy, 20 benzenesulfonyloxy, methanesulfonyloxy, toluenesulfonyloxy, azido, or -O-CO-(C₄-C₇ alkyl).

The term "haloformate" as used herein refers to an ester of a haloformic acid, this compound having the formula



wherein X is halo, and R^e is C₁-C₆ alkyl. Preferred haloformates are bromoformates and chloroformates. Especially preferred are chloroformates. Those haloformates wherein R³ is C₃-C₆ alkyl are 30 preferred. Most preferred is isobutyl chloroformate.

The compounds used in the method of the present invention may have one or more asymmetric centers. As a consequence of these chiral centers, the compounds of the present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as

- 9 -

well as diastereomers and mixtures of diastereomers. All asymmetric forms, individual isomers and combinations thereof, are within the scope of the present invention.

The terms "R" and "S" are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center. The term "R" (*rectus*) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The term "S" (*sinister*) refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The priority of groups is based upon their atomic number (in order of decreasing atomic number). A partial list of priorities and a discussion of stereochemistry is contained in NOMENCLATURE OF ORGANIC COMPOUNDS: PRINCIPLES AND PRACTICE, (J.H. Fletcher, *et al.*, eds., 1974) at pages 103-120.

In addition to the (R)-(S) system, the older D-L system is also used in this document to denote absolute configuration, especially with reference to amino acids. In this system a Fischer projection formula is oriented so that the number 1 carbon of the main chain is at the top. The prefix "D" is used to represent the absolute configuration of the isomer in which the functional (determining) group is on the right side of the carbon atom at the chiral center and "L", that of the isomer in which it is on the left.

In order to preferentially prepare one optical isomer over its enantiomer, the skilled practitioner can proceed by one of two routes. The practitioner may first prepare the mixture of enantiomers and then separate the two enantiomers. A commonly employed method for the resolution of the racemic mixture (or mixture of enantiomers) into the individual enantiomers is to first convert the enantiomers to diastereomers by way of forming a salt with an optically active acid or base. These diastereomers can then be separated using differential solubility, fractional crystallization, chromatography, or like methods. Further details regarding resolution of enantiomeric mixtures can be found in J. Jacques, *et al.*, ENANTIOMERS, RACEMATES, AND RESOLUTIONS, (1991).

- 10 -

In addition to the schemes described above, the practitioner of this invention may also choose an enantiospecific protocol for the preparation of the compounds of Formula I. Such a protocol employs a synthetic reaction design which maintains the chiral center present in 5 the starting material in a desired orientation. These reaction schemes usually produce compounds in which greater than 95 percent of the title product is the desired enantiomer.

As noted supra, this invention includes the pharmaceutically acceptable salts of the compounds defined by Formula 10 I. Although generally neutral, a compound of this invention can possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.

15 The term "pharmaceutically acceptable salt" as used herein, refers to salts of the compounds of the above formula which are substantially non-toxic to living organisms. Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a pharmaceutically acceptable 20 mineral or organic acid or an inorganic base. Such salts are known as acid addition and base addition salts.

Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids 25 such as *p*-toluenesulfonic, methanesulfonic acid, oxalic acid, *p*-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such pharmaceutically acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, 30 dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, 35 dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate,

- 11 -

phenylbutyrate, citrate, lactate, γ -hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid.

5 Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen carries a suitable 10 organic group such as an alkyl, alkenyl, alkynyl, or aralkyl moiety.

Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium 15 hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like. The potassium and sodium salt forms are particularly preferred.

It should be recognized that the particular counterion 20 forming a part of any salt of this invention is not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.

This invention further encompasses the pharmaceutically 25 acceptable solvates of the compounds of Formulas I. Many of the Formula I compounds can combine with solvents such as water, methanol, ethanol and acetonitrile to form pharmaceutically acceptable solvates such as the corresponding hydrate, methanolate, ethanolate and acetonitrilate.

30 This invention also encompasses the pharmaceutically acceptable prodrugs of the compounds of Formula I. A prodrug is a drug which has been chemically modified and may be biologically inactive at its site of action, but which may be degraded or modified by one or more enzymatic or other in vivo processes to the parent bioactive 35 form. This prodrug should have a different pharmacokinetic profile than the parent, enabling easier absorption across the mucosal

- 12 -

epithelium, better salt formation or solubility, or improved systemic stability (an increase in plasma half-life, for example).

Typically, such chemical modifications include:

- 1) ester or amide derivatives which may be cleaved by esterases or lipases;
- 2) peptides which may be recognized by specific or nonspecific proteases; or
- 3) derivatives that accumulate at a site of action through membrane selection of a prodrug form or a modified prodrug form;

10 or any combination of 1 to 3, *supra*. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in H, Bundgaard, DESIGN OF PRODRUGS, (1985).

The preferred methods of the present invention employ the preferred compounds of the present invention. The preferred compounds of the present invention are those compounds in which:

- (i) Z is a bond, methylenyl, or ethylenyl;
- (ii) at least one, but not more than three, of R², R³, R⁴, R⁵, and R⁶ are independently selected from the group consisting of chloro, fluoro, trifluoromethyl, methyl, ethyl, methoxy, ethoxy, methylamine, ethylamine, amino, methylthio, and ethylthio;
- (iii) R¹ is hydrogen, methyl, or acetyl; and
- (iv) X, when combined with the heterocyclic group to which it is attached forms 4-cyclohexylpiperazinyl, 4-(piperidin-1-yl)piperidin-1-yl, 4-phenylpiperazin-1-yl, 4-phenylpiperidin-1-yl, 4-dimethylaminopiperidin-1-yl; 4-diethylaminopiperidin-1-yl, 4-benzylpiperazin-1-yl, (4-methyl)-2,5-dioxopiperazin-1-yl, (4-phenyl)-2,5-dioxopiperazin-1-yl, (4-benzyl)-2,5-dioxopiperazin-1-yl; or a pharmaceutically acceptable salt, solvate, or prodrug of any such compound.

30 Especially preferred compounds include N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-

- 13 -

y1)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-
5 dimethylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-
10 diethylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,4-
15 bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-
20 trimethylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-
25 triethylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-
ethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-
30 yl)acetyl]amino]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-
35 yl)acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-
y1)acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-
y1)acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-
y1)acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-

- 15 -

trichlorobenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-methoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-chlorobenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[[[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-

- 16 -

chlorobenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-tri(trifluoromethyl)benzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-N-acetyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-(piperidin-1-yl)piperidin-1-yl)acetyl]amino]propanamide, N-(2-ethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-(piperidin-1-yl)piperidin-1-yl)acetyl]amino]propanamide, N-(2-methylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-(piperidin-1-yl)piperidin-1-yl)acetyl]amino]propanamide, N-(2-chlorobenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-(piperidin-1-yl)piperidin-1-yl)acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-(piperidin-1-yl)piperidin-1-yl)acetyl]amino]propanamide, N-(2-ethylbenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-(piperidin-1-yl)piperidin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-N-acetyl-3-(1H-indol-3-yl)-2-[(4-(piperidin-1-yl)piperidin-1-yl)acetyl]amino]propanamide.

yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-N-
acetyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-N-acetyl-3-(1H-
indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
5 yl]acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-N-acetyl-3-(1H-
indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-N-acetyl-3-(1H-
indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
10 yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-N-
acetyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-N-acetyl-3-(1H-
indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
15 yl]acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-N-acetyl-3-(1H-
indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-N-acetyl-3-(1H-
indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
20 yl]acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-N-acetyl-3-(1H-
indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-N-acetyl-3-(1H-
indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
25 yl]acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-N-
acetyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-
[[[4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-
30 ethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-
[[[4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-
chlorobenzyl)-3-(1H-indol-3-yl)-2-[[[4-methyl)-2,5-dioxopiperazin-1-
35 yl]acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-
yl)-2-[[[4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-
(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[[[4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-
2-[[[4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-
40 dimethylbenzyl)-3-(1H-indol-3-yl)-2-[[[4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-
[[[4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-

diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-
5 dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-
10 1-yl]acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
15 yl]acetyl]amino]propanamide, N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
20 yl]acetyl]amino]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
25 yl]acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
30 yl]acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-
35 dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-
40 dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide.

- 19 -

yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-methoxybenzyl)-3-

- 20 -

(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-(2-methoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-chlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide,

- 21 -

N-(2-ethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-chlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide.

yl)acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-N-methyl-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-ethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-methylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-chlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-ethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-N-methyl-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide.

yl]acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
5 yl]acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
10 yl]acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-N-methyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
yl]acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-N-methyl-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-
15 yl]acetyl]amino]propanamide, N-methyl-N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
20 yl]acetyl]amino]propanamide, N-methyl-N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
25 yl]acetyl]amino]propanamide, N-methyl-N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
30 yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
35 yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-

- 24 -

yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
5 yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
10 yl]acetyl]amino]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
15 yl]acetyl]amino]propanamide, N-methyl-N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
20 yl]acetyl]amino]propanamide, N-methyl-N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
25 yl]acetyl]amino]propanamide, N-methyl-N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide,
N-methyl-N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
30 yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
35 yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethylbenzyl)-3-(1H-

indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethoxybenzyl)-3-(1H-
indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethylbenzyl)-3-(1H-
5 indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trichlorobenzyl)-3-(1H-
indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-
10 (1H-indol-3-yl)-2-[(4-cyclohexyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-methoxybenzyl)-3-(1H-
indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-ethoxybenzyl)-3-(1H-indol-
3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-
15 methyl-N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-
dioxopiperazin-1-yl]acetyl]amino]propanamide, N-methyl-N-(2-
chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-trifluoromethylbenzyl)-3-
20 (1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-ethylbenzyl)-3-(1H-indol-3-
yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-
25 methyl-N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-
dioxopiperazin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4-
dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethoxybenzyl)-3-(1H-
30 indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethylbenzyl)-3-(1H-
indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dichlorobenzyl)-3-(1H-
35 indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-
indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethoxybenzyl)-3-
indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethylbenzyl)-3-(1H-
40 indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide. N-methyl-N-(3,4,5-triethoxybenzyl)-3-(1H-


- 26 -

indol-3-yl)-2-[[[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethylbenzyl)-3-(1H-
indol-3-yl)-2-[[[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trichlorobenzyl)-3-(1H-
5 indol-3-yl)-2-[[[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, and N-[3,4,5-trifluoromethyl]benzyl]-3-
(1H-indol-3-yl)-2-[[[(4-benzyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-methoxybenzyl)-3-(1H-
indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
10 yl]acetyl]amino]propanamide, N-methyl-N-(2-ethoxybenzyl)-3-(1H-indol-
3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide,
N-methyl-N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenyl)-2,5-
dioxopiperazin-1-yl]acetyl]amino]propanamide, N-methyl-N-(2-
chlorobenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
15 yl]acetyl]amino]propanamide, N-methyl-N-(2-trifluoromethylbenzyl)-3-
(1H-indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(2-ethylbenzyl)-3-(1H-indol-3-
yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-
methyl-N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenyl)-2,5-
20 dioxopiperazin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4-
dimethylbenzyl)-3-(1H-indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethoxybenzyl)-3-(1H-
indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethylbenzyl)-3-(1H-
25 indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dichlorobenzyl)-3-(1H-
indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-[3,5-bis(:trifluoromethyl)benzyl]-3-(1H-
indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
30 yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethoxybenzyl)-3-
(1H-indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethylbenzyl)-3-(1H-
indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethoxybenzyl)-3-(1H-
35 indol-3-yl)-2-[[[(4-phenyl)-2,5-dioxopiperazin-1-
yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethylbenzyl)-3-(1H-

- 27 -

indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]acetyl]amino]propanamide, and the salts, solvates, and prodrugs thereof.


5 A preferred process for preparing the compounds of Formula I is by the acylation of the primary amine of a compound of
 10 Formula II



15 or a salt or solvate thereof.

The acylation of this primary amine can be accomplished by a number of methods known in the art. One such reaction scheme is a substitution using an anhydride such as acetic anhydride or another activated carboxylate, such as a carboxylic acid halide.

20 Another preferred reaction scheme often employed to acylate a primary amine employs a carboxylic acid of Formula III



III

25

or a salt or solvate thereof, preferably with an activating agent, such as 1,1-carbonyldiimidazole, dicyclohexylcarbodiimide, diethyl


- 28 -

azodicarboxylate, 1-hydroxybenzotriazole, alkyl chloroformate and triethylamine, phenyldichlorophosphate, and chlorosulfonyl isocyanate.

An amino-de-alkoxylation type of reaction uses esters as a means of acylating the primary amine. Activated esters which are 5 attenuated to provide enhanced selectivity are very efficient acylating agents.

In an especially preferred embodiment, a compound of Formula III, or a salt thereof, is first reacted with a suitable haloformate, forming the mixed anhydride of Formula IIIa.

10




IIIa

This intermediate is then reacted with a compound of Formula II, or a 15 salt thereof, optionally in the presence of a base.

The intermediates of Formula II are generally prepared using techniques which are well known to those of skill in the art. See, e.g., Patent Cooperation Treaty published application WO 93/01169, published January 21, 1993. Once such synthesis scheme using 20 standard techniques is depicted in Scheme I, infra.


- 29 -

Scheme I



- 30 -


In an alternative embodiment the compounds of Formula I may be prepared from intermediates of Formula IV



5

IV

by reaction with compounds of Formula IVa.



10

IVa

This reaction is preferably performed in the presence of a coupling agent, such as dicyclohexylcarbodiimide.

15 Intermediates of Formula IV are commercially available or may be prepared by standard syntheses of amino acids. Such syntheses are well known to persons of ordinary skill in the art and are described, for example, in CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, (G.C. Chapman ed., 1985).


20 During any of the above synthetic sequences it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by conventional protecting groups as described supra.

- 31 -

The following Examples and Preparations are illustrative of the processes employed in the synthesis of the compounds of the present invention. As would be understood by persons skilled in the art, other synthetic schemes may be employed to prepare the compounds of the 5 instant invention.

Preparation 1

Preparation of 2-*t*-butoxycarbonylamino-3-(1H-indol-3-yl)-N-(2-methoxybenzyl)propanamide
10




To a solution of N-(*t*-butoxycarbonyl)tryptophan (46.4 g, 152.6 15 mmol) in 500 ml of dioxane was added carbonyl diimidazole (25.4 g, 156 mmol) in a portionwise manner. The resulting mixture was stirred for about 2.5 hours at room temperature and then stirred at 45°C for 30 minutes. Next, 2-methoxybenzylamine (20.7 ml, 158.7 mmol) was added and the reaction mixture was then stirred for 16 hours at room 20 temperature.

The dioxane was removed under reduced pressure. The product was partitioned between ethyl acetate and water and was washed successively with 1 N hydrochloric acid, saturated sodium bicarbonate solution, water, and brine, followed by drying over sodium 25 sulfate and removal of the solvent. Final crystallization from methanol yielded 52.2 g of homogeneous product as yellow crystals. Yield 80.8%. m.p. 157-160°C.

Preparation 2

- 32 -

Synthesis of 2-amino-3-(1H-indol-3-yl)-N-(2-methoxybenzyl)propanamide



5

To a mixture of the 2-*t*-butoxycarbonylamino-3-(1H-indol-3-yl)-N-(2-methoxybenzyl)propanamide prepared *supra* (25.1 g, 59.2 mmol) and anisole (12 ml, 110.4 mmol) at 0°C was added dropwise an aqueous solution of trifluoroacetic acid (118 ml, 1.53 mol) in 50 ml of water. This 10 mixture was stirred for one hour at 0°C, followed by stirring for about 2.5 hours at ambient temperature. The mixture was then refrigerated for about 16 hours.


15 The volatiles were removed under reduced pressure. The product was partitioned between ethyl acetate and saturated sodium bicarbonate solution and was then washed with water followed by brine and then dried over sodium sulfate. The solvents were removed *in vacuo*. Recrystallization from a 1:1 diethyl ether/cyclohexane solution yielded 18.0 g (94.2%) of homogeneous product as an off-white powder. m.p. 104-108°C.

20

Preparation 3

Preparation of 3-(1H-indol-3-yl)-2-(N-triphenylmethylamino)propanoic acid [N-trityltryptophan]

25



- 33 -


Chlorotrimethylsilane (70.0 ml, 0.527 mol) was added at a moderate rate to a stirring slurry of tryptophan (100.0 g, 0.490 mol) in anhydrous methylene chloride (800 ml) under a nitrogen atmosphere.

5 This mixture was continuously stirred for 4.25 hours. Triethylamine (147.0 ml, 1.055 mol) was added followed by the addition of a solution of triphenylmethyl chloride (147.0 g, 0.552 mol) in methylene chloride (400 ml) using an addition funnel. The mixture was stirred at room temperature, under a nitrogen atmosphere for at least 20 hours. The 10 reaction was quenched by the addition of methanol (500 ml).

The solution was concentrated on a rotary evaporator to near dryness and the mixture was redissolved in methylene chloride and ethyl acetate. An aqueous work-up involving a 5% citric acid solution (2X) and brine (2X) was then performed. The organic layer was 15 dried over anhydrous sodium sulfate, filtered, and concentrated to dryness on a rotary evaporator. The solid was dissolved in hot diethyl ether followed by the addition of hexanes to promote crystallization. By this process 173.6 g (0.389 mol) of analytically pure 3-(1H-indol-3-yl)-2-(N-triphenylmethylamino)propanoic acid was isolated as a light tan solid in 20 two crops giving a total of 79% yield.

Preparation 4

Preparation of 3-(1H-indol-3-yl)-N-(2-methoxybenzyl)-2-(N-triphenylmethylamino)propanamide



- 34 -

To a stirring solution of 3-(1H-indol-3-yl)-2-(N-triphenylmethylamino)propanoic acid (179.8 g, 0.403 mol), 2-methoxybenzylamine (56.0 ml, 0.429 mol), and hydroxybenzotriazole hydrate (57.97 g, 0.429 mol) in anhydrous tetrahydrofuran (1.7 L) and 5 anhydrous N,N-dimethylformamide (500 ml) under a nitrogen atmosphere at 0°C, were added triethylamine (60.0 ml, 0.430 mol) and 1-(3-dimethylaminopropyl)-3-ethoxycarbodiimide hydrochloride (82.25 g, 0.429 mol). The mixture was allowed to warm to room temperature under a nitrogen atmosphere for at least 20 hours. The mixture was 10 concentrated on a rotary evaporator and then redissolved in methylene chloride and an aqueous work-up of 5% citric acid solution (2X), saturated sodium bicarbonate solution (2X), and brine (2X) was performed. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness on a rotary evaporator. The title 15 product was then filtered as a pink solid in two lots. Isolated 215.8 g (0.381 mol) of analytically pure material (95% yield).

Analysis for C₃₈H₃₅N₃O₂:

Theory: C, 80.68; H, 6.24; N, 7.43.


Found: C, 80.58; H, 6.42; N, 7.45.

20

Preparation 5

Preparation of 2-amino-3-(1H-indol-3-yl)-N-(2-methoxybenzyl)propanamide

25



Formic acid (9.0 ml, 238.540 mmol) was added to a stirring solution of 3-(1H-indol-3-yl)-N-(2-methoxybenzyl)-2-(N-triphenylmethylamino)propanamide (14.11 g, 23.763 mmol) in anhydrous methylene chloride under a nitrogen atmosphere at 0°C.

After 4 hours, the reaction mixture was concentrated to an oil on a

- 35 -

rotary evaporator and redissolved in diethyl ether and 1.0 N hydrochloric acid. The aqueous layer was washed twice with diethyl ether and basified with sodium hydroxide to a pH greater than 12. The product was extracted out with methylene chloride (4X). The organic extracts 5 were combined, dried over anhydrous sodium sulfate, filtered, and concentrated on a rotary evaporator to a white foam. The compound 3-(1H-indol-3-yl)-2-amino-N-(2-methoxybenzyl)propanamide (7.52 g, 21.397 mmols) was isolated giving a 90% yield. No further purification was necessary.

10 Analysis for C₁₉H₂₁N₃O₂:


Theory: C, 73.76; H, 7.49; N, 13.58.

Found: C, 72.15; H, 7.78; N, 12.77.

Preparation 6

15

Preparation of 2-amino-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide




20 The title compound is prepared essentially as described above in Preparations 4 and 5 except that 2-chlorobenzylamine is employed instead of 2-methoxybenzylamine.

Preparation 7

25

Preparation of 2-t-butoxycarbonylamino-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide

- 36 -




To a solution of N-(*t*-butoxycarbonyl)tryptophan (21.28 g, 70 mmol) in 140 ml of acetone was added triethylamine (9.76 ml, 7.08 g, 70 mmol) in a portionwise manner. The resulting mixture was stirred for about thirty-five minutes at room temperature and then stirred at 45°C for 30 minutes under nitrogen. To the resulting mixture ethyl chloroformate (7.35 ml, 8.36 g, 77 mmol) was added with continued cooling and the reaction mixture was stirred for about one hour. Next, 2-chlorobenzylamine (9.30 ml, 10.9 g, 77 mmol) was added and the reaction mixture was then stirred until a white precipitate formed. The ice bath was removed and additional acetone was added. The reaction mixture was then stirred overnight.

The acetone was removed under reduced pressure. The residue was taken up in ethyl acetate (not all was soluble) and washed with dilute hydrochloric acid, followed by sodium hydroxide and then water. The solvents were removed by vacuum. After the addition of ether the reaction product was filtered and was washed with ether. Additional product was obtained by evaporating the ether filtrate. Yield >99%. NMR was consistent with the desired title product.

Preparation 8

Preparation of 2-amino-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide

25




5 A stirring solution of 2-*t*-butoxycarbonylamino-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide (6.00 g, 14 mmol) in 30 ml of 70% aqueous trifluoroacetic acid (21 ml trifluoroacetic acid, 9 ml water) was allowed to stir overnight at room temperature. The progress of this deprotection reaction was monitored by thin layer chromatography.

10 The solvents were removed in vacuo and the residue was taken up in acetonitrile, which was then removed by vacuum. The residue was partitioned between ether and 1 N sodium hydroxide. The organic solvent was removed by vacuum and the residue was taken up in methylene chloride. The residue was removed by filtration and washed with additional methylene chloride.

15 The filtrate and basic washes were combined, extracted with methylene chloride, and dried over sodium sulfate. The solvents were removed in vacuo. Yield 4.3 grams (93%). NMR was consistent with the desired title intermediate.

Preparation 9

20 Preparation of 2-bromoacetamido-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide



25 To a stirring solution of 2-amino-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide (4.39 g, 13.3 mmol) and sodium carbonate (2.73 g, 26.6 mmol) in 100 ml of dry tetrahydrofuran was added bromoacetyl bromide (2.32 ml, 5.37 g, 26.6 mmol). The resulting mixture was then stirred at room temperature for about one hour. The progress 30 of the reaction was monitored by thin layer chromatography.


- 38 -

The reaction mixture was stirred at room temperature overnight after the addition of more bromoacetyl bromide (about 0.5 ml). After the overnight stirring additional sodium carbonate (2.76 g) and bromoacetyl bromide (0.5 ml) were added and the reaction was stirred 5 an additional five minutes.

The reaction mixture was then poured into 600 ml of ethyl acetate and was washed three times with water, followed by washes with dilute hydrochloric acid, water and brine. The organic fraction was dried over sodium sulfate and the solvents were removed by 10 vacuum. Yield 5.24 g (88%). mp 182-184°C. The NMR was consistent with the desired title intermediate.

Preparation 10

15 Preparation of 2-chloroacetamido-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide




20 The title intermediate is prepared essentially as described in Preparation 9, *supra*, except that chloroacetyl chloride is employed in place of bromoacetyl bromide. mp 175-177.

Analysis for C₂₀H₁₉Cl₂N₃O₂:

25 Theory: C, 59.42; H, 4.74; N, 10.39.
Found: C, 59.21; H, 4.60; N, 10.12.

Preparation 11

Preparation of 2,5-dioxo-1,4-piperazinediacetic acid bis (1,1-dimethylethyl) ester and 2,5-dioxo-1-piperazineacetic acid 1,1-dimethylethyl ester



10 In a two liter round bottom flask, sodium hydride (60% dispersion in mineral oil, 24 g, 0.1 mol) was added to a slurry of glycine anhydride (11.4 g, 0.1 mol) in 1000 ml of N,N-dimethylformamide. The reaction was stirred for about six hours.

15 To the resulting mixture was then added t-butylbromoacetate (16.14 ml, 0.1 ml) in three portions. The resulting mixture was then stirred overnight at room temperature. The solvents were then removed by evaporation and the residue was taken up in ethyl acetate, and then filtered through CELITE®. The solvents were then removed by evaporation and the residue was extracted several times with hexanes to remove residual mineral oil.

20 The residue was then extracted with ether and redissolved in methylene chloride. The desired products were further purified and separated from each other by high performance liquid chromatography. mp 152-153°C.

25 Analysis for C₁₆H₂₆N₂O₄: [2,5-dioxo-1,4-piperazinediacetic acid bis (1,1-dimethylethyl) ester]

Theory: C, 56.13; H, 7.65; N, 8.18.

Found: C, 56.34; H, 7.46; N, 8.18.

- 40 -

Analysis for C₁₀H₁₆N₂O₄: [2,5-dioxo-1-piperazineacetic acid 1,1-dimethylethyl ester]

Theory: C, 52.62; H, 7.07; N, 12.27.


Found: C, 52.83; H, 7.05; N, 12.20.

5

Preparation 12

Preparation of 2,5-dioxo-1-piperazineacetic acid

10



In a 50 ml round bottom flask 5.0 ml of 70% trifluoroacetic acid was added to 2,5-dioxo-1-piperazineacetic acid 1,1-dimethylethyl ester (1.0 g) dissolved in anisole (1 ml). The reaction was

15 stirred at room temperature. The progress of the reaction was monitored by thin layer chromatography. The deprotection reaction was sufficiently complete after one hour.

The solvents were removed by evaporation. Acetonitrile was twice added to the residue and removed by evaporation. The residue 20 was taken up in acetonitrile, filtered, and washed with acetonitrile. The solvents were removed in vacuo to yield the desired title product. Yield 0.577 g. mp 160°C. IR was consistent with the predicted structure.


Analysis for C₆H₈N₂O₄:

Theory: C, 41.86; H, 4.68; N, 16.27.
25 Found: C, 41.37; H, 4.53; N, 15.95.

Preparation 13

Preparation of ethyl 3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]amino]propanoate

- 41 -



Carbonyldiimidazole (73.8 g, 455 mmol) was dissolved in 1.5 liters of dry acetonitrile. To this was added N-(*t*-butoxycarbonyl)glycine (80.0 g, 455 mmol) and the resulting mixture was heated at reflux for about thirty minutes. To the resulting mixture was added N-benzylglycine ethyl ester (85 ml, 45 mmol) and the reaction mixture was then heated at reflux overnight. The progress of the reaction was monitored by thin layer chromatography.

The reaction mixture was then stirred an additional 24 hours. The reaction mixture was concentrated in vacuo, and the residue partitioned between ethyl ether and 0.5 N hydrochloric acid. The organic fraction was washed with 0.5 N hydrochloric acid (three times until the wash was acidic). The organic fraction was then washed twice with a saturated sodium carbonate solution, followed by two washes with brine. The organic fraction was dried over sodium sulfate and the solvents were removed in vacuo to yield 130 grams of N-benzyl-1-[(*t*-butoxycarbonyl)amino]-N-(ethoxycarbonylmethyl)acetamide as a dark oil.

Trifluoroacetic acid (100 ml) was added to 40 ml of water and cooled to 0°C. The resulting solution was added to neat N-benzyl-1-[(*t*-butoxycarbonyl)amino]-N-(ethoxycarbonylmethyl)acetamide (130 g, 0.370 mol) and stirred overnight at room temperature. The progress of the reaction was monitored by thin layer chromatography.

- 42 -

An additional 40 ml of 70% trifluoroacetic acid were added and the solution was stirred at room temperature under a nitrogen atmosphere overnight. The solvents were then removed in vacuo. The residue was taken up in 100 ml of acetonitrile. The solvents were again removed in vacuo.

The residue was partitioned between ether and 1N hydrochloric acid. The ether fraction was extracted extensively with 1N hydrochloric acid. The aqueous fraction was basified to pH 12 with 5N sodium hydroxide, resulting in the formation of a white precipitate. The precipitate was removed by filtration, and then washed with water to yield 1-benzyl-2,5-dioxopiperazine (17.14 g, 23%).

In dry tetrahydrofuran (320 ml) was added 1-benzyl-2,5-dioxopiperazine (16.98 g, 83.0 mmol). The resulting slurry was cooled in an acetone/dry ice bath. While stirring under a nitrogen atmosphere, *n*-butyllithium (57 ml, 91.3 mmol) was added, and the resulting mixture was stirred for 45 minutes. The resulting mixture was then warmed in an ice bath and *t*-butylbromoacetate (14.7 ml, 91.3 mmol) was added. The resulting mixture was warmed to room temperature and was refluxed for four hours. The progress of the reaction was monitored by thin layer chromatography.

The solvents were removed in vacuo. The white residue was partitioned between 1N hydrochloric acid and ethyl acetate. The aqueous fraction was washed twice with ethyl acetate. The organic fractions were combined, washed twice with sodium carbonate, twice with brine, and then dried over sodium sulfate. The solvents were removed in vacuo (Fraction I).

The aqueous fraction, *supra*, was extracted twice with ethylene chloride. The ethylene chloride extract was washed twice with sodium carbonate, twice with brine, and then dried over sodium sulfate. The solvents were removed in vacuo. The residue was triturated with ether to yield Fraction II.

Fraction I and Fraction II were combined to yield 8.7 grams (33%) of 1-benzyl-4-(*t*-butoxycarbonylmethyl)-2,5-dioxopiperazine.

Trifluoroacetic acid (100 ml of a 70% solution) was cooled in an ice bath under a nitrogen atmosphere and then 1-benzyl-4-(*t*-butoxycarbonylmethyl)-2,5-dioxopiperazine (8.7 g, 27.4 mmol) was

- 43 -

added. The resulting mixture was then allowed to room temperature at which temperature it was stirred for four hours. The progress of the reaction was monitored by thin layer chromatography.

The solvents were removed in vacuo. The residue was 5 dissolved in acetonitrile. The acetonitrile was then removed in vacuo. The deprotected intermediate, 1-[4-benzyl-2,5-dioxopiperazin-1-yl]acetic acid (5.54 g, 77%), was recrystallized from acetonitrile.

10 1-[4-Benzyl-2,5-dioxopiperazin-1-yl]acetic acid (5.32 g, 20 mmol) was dissolved in 350 ml tetrahydrofuran under a nitrogen atmosphere. To this solution was added DL-tryptophan ethyl ester (5.38 g, 20 mmol), followed by hydroxybenztriazole hydrate (2.97 g, 22 mmol) and triethylamine (3.67 ml, 22 mmol). The resulting mixture was then cooled to 0°C and 1-ethyl-3-[3-dimethylamino)propyl]carbodiimide hydrochloride (4.3 g, 22 mmol) was added, resulting in the formation of 15 a precipitate. An additional 350 ml of tetrahydrofuran was added to re-dissolve the precipitate.

20 The reaction mixture slowly warmed to room temperature as the ice bath melted, and the reaction mixture was stirred overnight and the progress of the reaction was monitored by thin layer chromatography. An additional 1.4 grams of the tryptophan ethyl ester was added and the resulting reacton mixture was then allowed to stir overnight at room temperature.

25 The raction mixture was concentrated in vacuo and then washed twice with a saturated sodium carbonate solution, twice with brine, and then dried over sodium sulfate. The solvents were removed in vacuo. The desired product was further purified by liquid chromatography. Some of the fractions were further purified by dissolving in ethylene chloride, washed twice with 1N hydrochloric acid, twice with brine, and then dried over sodium sulfate. The solvents were 30 removed in vacuo to yield 4.68 grams (98%) of the desired title product, ethyl 3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]amino]propanoate. mp 87.8-89.0°C. NMR was consistent with the desired title product.

FDMS 476 (M+).

35 Analysis for C₂₆H₂₈N₄O₅:


Theory: C, 65.53; H, 5.92; N, 11.76.

- 44 -

Found: C, 65.83; H, 6.00; N, 11.94.

Preparation 14

5 Preparation of 3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetamido]propanoic acid



10 In a one liter round bottom flask under a nitrogen atmosphere were mixed DL-tryptophan (20.4 mg, 0.10 mol) and potassium carbonate (13.8 mg, 0.10 mol) in 500 ml dry tetrahydrofuran. To the resulting slurry, which was cooled in an ice bath, bromoacetyl bromide (8.72 ml, 20.2 mg, 0.10 mol) was added portionwise 15 over about fifteen minutes. The resulting mixture was then allowed to warm to room temperature with continued stirring. The progress of the reaction was monitored by thin layer chromatography.

20 The solvents were removed in vacuo. The residue was then partitioned between water and ethyl acetate. The aqueous fraction was neutralized by the addition of 5 N hydrochloric acid. The aqueous fraction was then extracted thrice with ethyl acetate. The organic fractions were combined, washed with brine, and then dried over sodium sulfate. The solvents were removed in vacuo to yield an oil. The desired intermediate, (+)- α -(bromoacetyl)tryptophan, was then 25 recrystallized from chloroform. mp 135-136°C.

Analysis for C₁₃H₁₃BrN₂O₃:

Theory: C, 48.02; H, 4.03; N, 8.61.

Found: C, 47.82; H, 4.05; N, 8.40.

- 45 -

In 200 ml of tetrahydrofuran in a 500 ml round bottom flask under a nitrogen atmosphere was added (+)- α -(bromoacetyl)tryptophan (3.25 mg, 0.01 mol), followed by 4-phenylpiperazine (3.24 mg, 3.1 ml, 0.02 mol), added portionwise over five minutes. Three minutes after addition 5 of the 4-phenylpiperazine, a precipitate formed. The reaction mixture was stirred at room temperature for about 18 hours.

The precipitate was removed by filtration and washed with ether. The filtrate was evaporated. To the evaporated filtrate, sodium hydroxide (12.6 ml of a 1N solution) was added. The resulting mixture 10 was extracted twice with ether. The aqueous fraction was acidified by the addition of 13.6 ml of 1N hydrochloric acid. This aqueous fraction was then extracted thrice with ethanol. The organic fractions were combined and extracted with brine. The solvents were removed in vacuo. The desired title intermediate was recrystallized from 15 chloroform. mp 193-194°C. FDMS 406, 407, 408.

Analysis for C₂₃H₂₆N₄O₃:

Theory: C, 67.96; H, 6.45; N, 13.78.


Found: C, 66.86; H, 6.34; N, 13.46.

20

Preparation 15

Preparation of 3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetamido]propanoic acid

25




The title product is prepared essentially as described in Preparation 14, supra, except that an equimolar amount of 4-cyclohexylpiperazine is employed instead of the 4-phenylpiperazine 30 employed therein.

- 46 -

Preparation 16


5 Preparation of 3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-
yl]acetamido]propanoic acid



10 The title product is prepared essentially as described in
Preparation 14, *supra*, except that an equimolar amount of 4-(piperidin-1-yl)piperidine is employed instead of the 4-phenylpiperazine employed
therein.

Preparation 17

15 Preparation of 3-(1H-indol-3-yl)-2-[[[(4-benzyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]amino]propanoic acid



- 47 -

In a 100 ml round bottom flask ethyl 3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]amino]propanoate (8.63 g, 18.0 mmol) was dissolved in 300 ml of methanol. Aqueous sodium hydroxide (18 ml of a 5N solution, 90 mmol) was added and the solution was stirred under nitrogen atmosphere for about three hours. The progress of the reaction was monitored by thin layer chromatography.

The solution was acidified to pH 1.0 with 1 N hydrochloric acid and was then extracted extensively with chloroform. The solvents were removed in vacuo to yield 7.18 grams (89%) of the desired title intermediate.

FDMS 448 (M⁺). mp 219-220°C.
1H NMR: DMSO δ 2.97 (dd, J=8, 15Hz, 1H), 3.13 (dd, J=5, 14 Hz, 1H), 3.85 (s, 2H), 3.85-4.01 (m, 4H), 4.40-4.60 (m, 3H), 6.80-7.10 (m, 3H), 7.20-7.45 (m, 6H), 7.50 (d, J=8 Hz, 1H), 8.34 (d, J=8 Hz, 1H), 10.83 (s, 1H), 12.65 (brs, 1H).

Analysis for C₂₄H₂₄N₄O₅:

Theory: C, 64.28; H, 5.39; N, 12.49.


Found: C, 64.50; H, 5.37; N, 12.74.

20

Example 1

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzylpiperidin-1-yl)acetyl]amino]propanamide hydrochloride salt

25



- 48 -

To a stirring solution of 2-bromoacetamido-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide (0.897 g, 2 mmol) in 40 ml of tetrahydrofuran was added 4-benzylo哌啶 (0.70 ml, 0.70 g, 4 mmol). The resulting mixture was stirred at room temperature as the progress 5 of the reaction was monitored by thin layer chromatography. After about 1.75 hours, ether was added to the reaction mixture and the organic fraction was washed with water, dilute sodium carbonate, water, and then brine sequentially.

The organic fraction was dried over sodium sulfate and the 10 solvents were removed in vacuo to yield 1.17 grams of a foam. To this foam were added ethanol and 4 ml of 1 N hydrochloric acid. The resulting mixture was filtered and washed with ether. To the residue was added methylene chloride. The resulting crystals were removed by filtration and washed with methylene chloride to yield 0.92 g (79%) of the 15 desired title product. mp 189-190°C. FDMS 543, 545, 546, 547. NMR was consistent with the desired title product.

Analysis for C₃₂H₃₅ClN₄O₂ • HCl:

Theory: C, 66.32; H, 6.26; N, 9.67.


Found: C, 66.54; H, 6.33; N, 9.35.

20

Example 2

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(2,5-dioxopiperazin-1-yl)methyl]carbonylamino]propanamide

25



- 49 -

The acid prepared in Preparation 12 (96 mg, 5.58 mmol) is admixed with carbonyldiimidazole (91 mg, 5.58 mmol) in the presence of acetonitrile (20 ml) and dioxane (10 ml). The resulting mixture was then stirred for about thirty minutes. To this mixture was then added 2-
5 amino-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide (0.183 g, 5.58 mmol). The resulting mixture was heated to reflux and allowed to reflux overnight.

The solvents were then removed in vacuo. Ethyl acetate was then added and the resulting mixture was filtered. The filtrate was 10 washed subsequently with water, dilute hydrochloric acid, water, a concentrated sodium carbonate solution, water, and a saturate sodium chloride solution. The organic fraction was dried over sodium sulfate and filtered. The solvents were removed by vacuum to yield the desired title product. The IR, NMR, and UV spectra were consistent with the 15 title product.

Analysis for C₂₄H₂₄N₅O₄Cl:


Theory: C, 59.81; H, 5.02; N, 14.53.

Found: C, 59.84; H, 5.03; N, 14.49.

20

Example 3

Preparation of N-benzyl-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonylamino]propanamide



25

- 50 -

In a 100 ml round bottom flask 3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]amino]propanoic acid (0.300 g, 0.67 mmol) was dissolved in 12 ml of dry tetrahydrofuran. To 5 the resulting mixture were added benzylamine (0.088 ml, 0.80 mmol), 1-hydroxybenzotriazole hydrate (0.12 g, 0.87 mmol), and triethylamine (0.12 ml, 0.87 mmol) while stirring under a nitrogen atmosphere. The resulting mixture was then cooled to 0°C and 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (0.17 g, 0.87 mmol) 10 was added.

The resulting mixture was then permitted to warmed to room temperature and was then stirred overnight. The progress of the reaction was monitored by thin layer chromatography.


The reaction mixture was concentrated in vacuo. The 15 residue was dissolved in chloroform, washed twice with 5% aqueous citric acid, and then twice with a saturated sodium carbonate solution. The organic fraction was concentrated by vacuum, and the desired product was further purified by chromatography. Yield (290 mg, 80%). The NMR was consistent with the predicted structure. FDMS (M+) 537. 20 $\text{CDCl}_3 \delta$ 3.17 (dd, $J=8, 15$ Hz, 1H), 3.33 (dd, $J=8, 15$ Hz, 1H), 3.46-3.70 (m, 2H), 3.76-4.00 (m, 4H), 4.23 (dd, $J=6, 15$ Hz, 1H), 4.33 (dd, $J=6, 15$ Hz, 1H), 4.40-4.56 (m, 2H), 4.80 (m, 1H), 6.55 (br s, 1H), 6.83-6.96 (m, 2H), 6.96-7.40 (m, 13H), 7.63 (d, $J=8$ Hz, 1H), 8.27 (s, 1H)
Analysis for $\text{C}_{31}\text{H}_{31}\text{N}_5\text{O}_4$:

25 Theory: C, 69.26; H, 5.81; N, 13.03.
 Found: C, 69.23; H, 5.91; N, 12.79.

Example 4

30 Preparation of N-phenyl-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]amino]propanamide

- 51 -



The title compound was prepared essentially as described in Example 3, *supra*, except that an equimolar amount of aniline was employed instead of benzylamine. Yield (250 mg, 71%). The NMR was consistent with the predicted structure. mp 158.5-160°C. FDMS (M+) 523.

DMSO δ 3.03 (m, 1H), 3.15 (m, 1H), 3.80-4.10 (m, 6H), 4.50 (s, 2H), 4.68 (m, 1H), 6.90-7.10 (m, 4H), 7.15 (s, 1H), 7.20-7.40 (m, 7H), 7.50-7.70 (m, 3H), 8.46 (d, J=8 Hz, 1H), 10.07 (s, 1H), 10.82 (s, 1H)

Analysis for C₃₀H₂₉N₅O₄:

Theory: C, 68.82; H, 5.58; N, 13.38.


Found: C, 69.04; H, 5.39; N, 13.18.

15

Example 5

Preparation of N-phenylethyl-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]amino]propanamide

- 52 -



The title compound was prepared essentially as described in Example 3, *supra*, except that an equimolar amount of 2-phenylethylamine was employed instead of benzylamine. Yield (200 mg, 52%). The NMR was consistent with the predicted structure. FDMS (M+) 551.


Analysis for C₃₂H₃₃N₅O₄:

Theory: C, 69.67; H, 6.03; N, 12.69.
10 Found: C, 69.56; H, 6.11; N, 12.79.

Example 6

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]amino]propanamide
15

- 53 -




The desired title product was prepared essentially as described in Example 3 except that 2-chlorobenzylamine was employed instead of benzylamine.
5 The NMR was consistent with the predicted structure. mp 214-215°C.
FDMS (M+) 571.
Analysis for C₃₁H₃₀ClN₅O₄:

Theory: C, 65.09; H, 5.29; N, 12.24.
10 Found: C, 65.65; H, 5.29; N, 12.08.

Example 7

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(piperidin-1-yl)acetyl]amino]propanamide
15



- 54 -

To a stirring solution of 2-bromoacetamido-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide (0.897 g, 2 mmol) in 40 ml of tetrahydrofuran were added piperidine hydrochloride (0.486 g, 4 mmol) and potassium carbonate (0.55 g, 4 mmol). The resulting mixture was 5 stirred at room temperature as the progress of the reaction was monitored by thin layer chromatography. After about two hours, additional potassium carbonate (0.55 g) and piperidine hydrochloride (0.49 g) were added, the resulting solution was heated to reflux and maintained at that temperature for about 5.5 hours. The reaction 10 mixture was allowed to cool, at which time 2.0 ml of piperidine (free base) was added after which the reaction mixture was stirred for an additional forty minutes.

Ether was then added to the reaction mixture and the 15 organic fraction was washed with water, dilute sodium carbonate, water, and then brine sequentially.


The organic fraction was dried over sodium sulfate and the solvents were removed in vacuo to yield 1.20 grams as a foam. The desired product was further purified by flash chromatography. NMR 20 was consistent with the desired title product.

20

Example 8

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methylpiperazin-1-yl)acetyl]amino]propanamide

25



- 55 -

The title compound is prepared essentially as described in Example 7, *supra*, except that N-methylpiperazine is employed in place of piperidine hydrochloride. mp 186-187°C. Yield 0.72 g (77%). NMR, IR, and UV were consistent with the proposed title structure. FDMS 5 466, 468, 469.


Analysis for $C_{25}H_{30}ClN_5O_2$:

Theory: C, 64.16; H, 6.46; N, 14.96.
Found: C, 63.86; H, 6.46; N, 14.66.

10

Example 9

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide



15

The title compound is prepared essentially as described in Example 7, *supra*, except that N-phenylpiperazine is employed in place of piperidine hydrochloride. mp 150-155°C. Yield 0.68 g (63%). NMR, IR, and UV were consistent with the proposed title structure. FDMS 20 529, 531.

Analysis for $C_{30}H_{32}ClN_5O_2$:


Theory: C, 67.98; H, 6.07; N, 13.21.
Found: C, 67.77; H, 6.08; N, 12.96.

25

Example 10

- 56 -

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperidin-1-yl)acetyl]amino]propanamide



5

The title compound is prepared essentially as described in Example 7, supra, except that 4-phenylpiperidine is employed in place of piperidine hydrochloride. mp 134-135°C. Yield 0.83 g (86%). NMR, IR, and UV were consistent with the proposed title structure. FDMS 528.
10 Analysis for C₃₁H₃₃ClN₄O₂:

Theory: C, 70.37; H, 6.29; N, 10.59.


Found: C, 70.07; H, 6.44; N, 10.60.

15

Example 11

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide

- 57 -




The title compound is prepared essentially as described in Example 7, supra, except that N-cyclohexylpiperazine is employed in place of piperidine hydrochloride. mp 150-155°C. Yield 0.68 g (63%).
5 NMR, IR, and UV were consistent with the proposed title structure.
FDMS 529, 531.

Analysis for $C_{30}H_{32}ClN_5O_2$:

Theory: C, 67.98; H, 6.07; N, 13.21.
10 Found: C, 67.77; H, 6.08; N, 12.96.

Example 12

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-(piperidin-1-yl)piperidin-1-yl)acetyl]amino]propanamide
15




- 58 -

The title compound is prepared essentially as described in Example 7, supra, except that 4-(piperidin-1-yl)piperidine is employed in place of piperidine hydrochloride. mp 134-135°C. Yield 0.83 g (86%).

5 NMR, IR, and UV were consistent with the proposed title structure.
FDMS 528.

Example 13

10 Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzylpiperazin-1-yl)acetyl]amino]propanamide dihydrochloride salt



15 To a stirring solution of 2-chloroacetamido-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide (0.61 g, 1.49 mmol) in 30 ml of dry tetrahydrofuran was added 1-benzylpiperazine (0.522 ml, 3 mmol). The resulting reaction mixture was stirred at room temperature for about 16 hours. The progress of the reaction was monitored by thin layer chromatography.

20 The reaction mixture was then warmed for one hour and then heated to reflux, at which temperature the reaction mixture was maintained for about 3.5 hours. The solvents were removed in *vacuo*, and the residue was taken up in a 1:1 ether:ethyl acetate mixture, which was washed with dilute hydrochloric acid. These acidic extracts were combined and basified with sodium carbonate. This was then extracted four times with ethyl acetate. These organic fractions were combined, washed with brine, and dried over sodium sulfate.

- 59 -

The dihydrochloride salt was made by the addition of dilute hydrochloride acid (5 ml) to the free base in ethanol. The solvents were removed in *vacuo* and the crystals were harvested by filtration, and then washed with ethanol. Yield 0.85 grams. mp 205-210°C. NMR and IR were consistent with proposed title compounds.

5 Analysis for C₃₁H₃₄ClN₅O₂ • 2HCl:

Theory: C, 60.35; H, 5.88; N, 11.35.


Found: C, 60.45; H, 6.10; N, 11.58.

10

Example 14

Preparation of N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide

15



20

A stirring solution of 3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetamido]propanoic acid (0.41 g, 1 mmol), prepared as described in Preparation 14 *supra*, in 25 ml of dioxane was heated and carbonyldiimidazole (0.16 g, 1 mmol) was added. The resulting mixture was heated until all materials were dissolved. At that time 2-methoxybenzylamine (0.108 ml, 0.14 g, 1 mmol) was added. The resulting mixture was heated for one hour. The progress of the reaction was monitored by thin layer chromatography.

25

After the reaction was substantially complete, the solvents were removed in *vacuo*. The residue was partitioned between ethyl

- 60 -

acetate and water. The organic fraction was washed sequentially with water, a sodium carbonate solution, twice with water, and then brine. The organic fraction was then dried over sodium sulfate and the solvents were removed in vacuo.


5 The desired title product was further purified by flash chromatography to yield 0.214 grams. mp 172-174. FDMS 525. IR and UV were consistent with the desired title product.

Analysis for C₃₁H₃₅N₅O₃:

Theory: C, 70.83; H, 6.71; N, 13.32.
10 Found: C, 71.09; H, 6.89; N, 13.04.

Example 15

15 Preparation of N-benzyl-N-methyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide



20 The desired title product was prepared essentially as described in Example 14, *supra*, except that an equimolar amount of N-benzylmethylamine was employed in place of the 2-methoxybenzylamine employed therein.

FDMS 509. NMR and UV were consistent with the above title structure.


Analysis for C₃₁H₃₅N₅O₂:

25 Theory: C, 73.06; H, 6.92; N, 13.74.
Found: C, 72.78; H, 6.95; N, 13.88.

- 61 -

Example 16

Preparation of N-benzyl-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide



The desired title product was prepared essentially as
10 described in Example 14, *supra*, except that an equimolar amount of
benzylamine was employed in place of the 2-methoxybenzylamine
employed therein.
FDMS 495. mp 154-156°C. NMR, UV, and IR were consistent with the
above title structure.

15 Analysis for C₃₀H₃₃N₅O₂:


Theory: C, 72.70; H, 6.71; N, 14.31.

Found: C, 72.52; H, 6.60; N, 13.93.

Example 17

20 Preparation of N-(4-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide

- 62 -



The desired title product was prepared essentially as described in Example 14, *supra*, except that an equimolar amount of 4-chlorobenzylamine was employed in place of the 2-methoxybenzylamine employed therein.


FDMS 529. mp 204-205°C. NMR, IR, and UV were consistent with the above title structure.

Analysis for $C_{30}H_{35}ClN_5O_2$:

Theory: C, 67.98; H, 6.09; N, 13.21.
 Found: C, 68.05; H, 6.22; N, 13.06.

Example 18

Preparation of N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonylamino]propanamide



- 63 -

The desired title product was prepared essentially as described in Example 6 except that an equimolar amount of 3-(1H-indol-3-yl)-2-[(4-methyl-2,5-dioxopiperazin-1-yl)methyl]carbonyl]amino]propanoic acid was employed instead of the 3-(1H-indol-3-yl)-2-[(4-benzyl-2,5-dioxopiperazin-1-yl)methyl]carbonyl]amino]propanoic acid employed therein. The NMR was consistent with the predicted structure. mp 197-198°C. FDMS (M+) 495, 497, 498.

10 Analysis for C₂₅H₂₆ClN₅O₄:

Theory: C, 60.54; H, 5.28; N, 14.12.

Found: C, 60.83; H, 5.43; N, 14.29.

15 The biological activity of the compounds of the present invention is evaluated employing an initial screening assay which rapidly and accurately measured the binding of the tested compound to known NK-1 and NK-2 receptor sites. Assays useful for evaluating tachykinin receptor antagonists are well known in the art. See, e.g., J. Jukic, et al., Life Sciences, 49:1463-1469 (1991); N. Kucharczyk, et al., Journal of Medicinal Chemistry, 36:1654-1661 (1993); N. Rouissi, et al., Biochemical and Biophysical Research Communications, 176:894-901 (1991).

25 NK-1 Receptor Binding Assay

30 Radioreceptor binding assays are performed using a derivative of a previously published protocol. D.G. Payan, et al., Journal of Immunology, 133:3260-3265 (1984). In this assay an aliquot of IM9 cells (1 x 10⁶ cells/tube in RPMI 1604 medium supplemented with 10% fetal calf serum) is incubated with 20 pM ¹²⁵I-labeled substance P in the presence of increasing competitor concentrations for 45 minutes at 4°C.

35 The IM9 cell line is a well-characterized cell line which is readily available to the public. See, e.g., Annals of the New York Academy of Science, 190: 221-234 (1972); Nature (London), 251:443-444 (1974); Proceedings of the National Academy of Sciences (USA), 71:84-88

- 64 -

(1974). These cells are routinely cultured in RPMI 1640 supplemented with 50 µg/ml gentamicin sulfate and 10% fetal calf serum.

5 The reaction is terminated by filtration through a glass fiber filter harvesting system using filters previously soaked for 20 minutes in 0.1% polyethylenimine. Specific binding of labeled substance P is determined in the presence of 20 nM unlabeled ligand.

10 Many of the compounds employed in the methods of the present invention are also effective antagonists of the NK-2 receptor.

NK-2 Receptor Binding Assay

15 The CHO-hNK-2R cells, a CHO-derived cell line transformed with the human NK-2 receptor, expressing about 400,000 such receptors per cell, are grown in 75 cm² flasks or roller bottles in minimal essential medium (alpha modification) with 10% fetal bovine serum. The gene sequence of the human NK-2 receptor is given in N.P. Gerard, *et al.*, *Journal of Biological Chemistry*, 265:20455-20462 (1990).

20 For preparation of membranes, 30 confluent roller bottle cultures are dissociated by washing each roller bottle with 10 ml of Dulbecco's phosphate buffered saline (PBS) without calcium and magnesium, followed by addition of 10 ml of enzyme-free cell dissociation solution (PBS-based, from Specialty Media, Inc.). After an additional 15 minutes, the dissociated cells are pooled and centrifuged at 25 1,000 RPM for 10 minutes in a clinical centrifuge. Membranes are prepared by homogenization of the cell pellets in 300 ml 50 mM Tris buffer, pH 7.4 with a Tekmar® homogenizer for 10-15 seconds, followed by centrifugation at 12,000 RPM (20,000 x g) for 30 minutes using a Beckman JA-14® rotor. The pellets are washed once using the above 30 procedure, and the final pellets are resuspended in 100-120 ml 50 mM Tris buffer, pH 7.4, and 4 ml aliquots stored frozen at -70°C. The protein concentration of this preparation is 2 mg/ml.

35 For the receptor binding assay, one 4-ml aliquot of the CHO-hNK-2R membrane preparation is suspended in 40 ml of assay buffer containing 50 mM Tris, pH 7.4, 3 mM manganese chloride, 0.02% bovine serum albumin (BSA) and 4 µg/ml chymostatin. A 200 µl volume

- 65 -

of the homogenate (40 µg protein) is used per sample. The radioactive ligand is [¹²⁵I]iodohistidyl-neurokinin A (New England Nuclear, NEX-252), 2200 Ci/mmol. The ligand is prepared in assay buffer at 20 nCi per 100 µl; the final concentration in the assay is 20 pM.

5 Non-specific binding is determined using 1 µM eledoisin. Ten concentrations of eledoisin from 0.1 to 1000 nM are used for a standard concentration-response curve.

10 All samples and standards are added to the incubation in 10 µl dimethylsulfoxide (DMSO) for screening (single dose) or in 5 µl DMSO for IC₅₀ determinations. The order of additions for incubation is 190 or 195 µl assay buffer, 200 µl homogenate, 10 or 5 µl sample in DMSO, 100 µl radioactive ligand. The samples are incubated 1 hour at room temperature and then filtered on a cell harvester through filters which had been presoaked for two hours in 50 mM Tris buffer, pH 7.7, containing 0.5% BSA. The filter is washed 3 times with approximately 3 ml of cold 50 mM Tris buffer, pH 7.7. The filter circles are then punched into 12 x 75 mm polystyrene tubes and counted in a gamma counter.

20 Table I, infra, depicts the results of several such neurokinin binding assays. Column 1 provides the example number of the test antagonist compound as detailed supra. The next columns define the the concentration of the test compound (in nanomolar quantities) which inhibits fifty percent of the binding of the appropriate neurokinin, as defined in the column heading. Certain values may 25 represent the average of more than one experiment.

Table I

Binding Affinities of Compounds of Formula I

30

Example No.	NK-1 IC ₅₀ nM	NK-2 IC ₅₀ nM
1	290	330

2

230

1500

- 66 -

3		1500
4		2100
5		740
6	41	82
7	730	2200
8	78	3400
9	30	240
10	140	570
13	34	240
14	67	650
15	180	
16	140	430
17	210	210
18	95	3100

As the compounds of Formula I are effective tachykinin receptor antagonists, these compounds are of value in the treatment of a wide variety of clinical conditions which are characterized by the presence of an excess of tachykinin. Thus, the invention provides

methods for the treatment or prevention of a physiological disorder associated with an excess of tachykinins, which method comprises administering to a mammal in need of said treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable 5 salt, solvate or prodrug thereof. The term "physiological disorder associated with an excess of tachykinins" encompasses those disorders associated with an inappropriate stimulation of tachykinin receptors, regardless of the actual amount of tachykinin present in the locale.

These physiological disorders may include disorders of the 10 central nervous system such as anxiety, depression, psychosis, and schizophrenia; neurodegenerative disorders such as dementia, including senile dementia of the Alzheimer's type, Alzheimer's disease, AIDS-associated dementia, and Down's syndrome; demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis 15 and other neuropathological disorders such as peripheral neuropathy, such as diabetic and chemotherapy-induced neuropathy, and post-herpetic and other neuralgias; acute and chronic obstructive airway diseases such as adult respiratory distress syndrome, bronchopneumonia, bronchospasm, chronic bronchitis, drivercough, 20 and asthma; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrosis, osteoarthritis, and rheumatoid arthritis; disorders of the musculo-skeletal system, such as osteoporosis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, 25 and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatites; addiction disorders such as alcoholism; stress-related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of 30 transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosis; gastrointestinal disorders or diseases associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease, emesis, and irritable bowel syndrome; disorders of bladder function such as bladder detrusor 35 hyper-reflexia and incontinence; atherosclerosis; fibrosis and collagen diseases such as scleroderma and eosinophilic fascioliasis;

irritative symptoms of benign prostatic hypertrophy; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine, and Reynaud's disease; and pain or nociception, for example, that attributable to or associated with any of the foregoing conditions, 5 especially the transmission of pain in migraine. For example the compounds of Formula I may suitably be used in the treatment of disorders of the central nervous system such as anxiety, psychosis, and schizophrenia; neurodegenerative disorders such as Alzheimer's disease and Down's syndrome; respiratory diseases such as 10 bronchospasm and asthma; inflammatory diseases such as inflammatory bowel disease, osteoarthritis and rheumatoid arthritis; adverse immunological disorders such as rejection of transplanted tissues; gastrointestinal disorders and diseases such as disorders associated with the neuronal control of viscera such as ulcerative colitis, 15 Crohn's disease, emesis, and irritable bowel syndrome; incontinence; disorders of blood flow caused by vasodilation; and pain or nociception, for example, that attributable to or associated with any of the foregoing conditions or the transmission of pain in migraine.

Many of the compounds of Formula I are selective 20 tachykinin receptor antagonists. These compounds preferentially bind one tachykinin receptor subtype compared to other such receptors. Such compounds are especially preferred.

For example, NK-1 antagonists are most especially preferred in the treatment of pain, especially chronic pain, such as 25 neuropathic pain, post-operative pain, and migraines, pain associated with arthritis, cancer-associated pain, chronic lower back pain, cluster headaches, herpes neuralgia, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting 30 from burns, including sunburn, post partum pain, angina pain, and genitourinary tract-related pain including cystitis.

In addition to pain, NK-1 antagonists are especially preferred in the treatment and prevention of urinary incontinence; 35 irritative symptoms of benign prostatic hypertrophy; motility disorders of the gastrointestinal tract, such as irritable bowel syndrome; acute and chronic obstructive airway diseases, such as bronchospasm,

- 69 -

bronchopneumonia, asthma, and adult respiratory distress syndrome; atherosclerosis; inflammatory conditions, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, osteoarthritis, neurogenic inflammation, allergies, rhinitis, cough, 5 dermatitis, urticaria, psoriasis, conjunctivitis, emesis, irritation-induced miosis; tissue transplant rejection; plasma extravasation resulting from cytokine chemotherapy and the like; spinal cord trauma; stroke; cerebral stroke (ischemia); Alzheimer's disease; Parkinson's disease; multiple sclerosis; amyotrophic lateral sclerosis; 10 schizophrenia; anxiety; and depression.

NK-2 antagonists are especially preferred in the treatment of urinary incontinence, bronchospasm, asthma, adult respiratory distress syndrome, motility disorders of the gastrointestinal tract, such as irritable bowel syndrome, and pain.

15 Recent reports have demonstrated that the co-administration of an NK-1 antagonist and an NK-2 antagonist has a synergistic advantage over either alone. United Kingdom Patent Application GB 2,274,777 A, published August 10, 1994. This line of reasoning would suggest, therefore, that a compound of Formula I 20 which has antagonist activity at both the NK-1 and NK-2 receptors, even though neither such activity is optimal when compared to the other compounds of Formula I, may be preferable to a compound having optimal activity at one or the other receptor.

25 The compounds of Formula I are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the 30 pharmaceutical art and comprise at least one active compound.

35 The present invention also includes pharmaceutical compositions which contain, as the active ingredient, the compounds of Formula I associated with pharmaceutically acceptable carriers. In making the compositions of the present invention the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet,

- 70 -

paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, 5 suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the 10 active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a 15 substantially uniform distribution in the formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, 20 microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and 25 flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

The compositions are preferably formulated in a unit 30 dosage form, each dosage containing from about 0.05 to about 100 mg, more usually about 1.0 to about 30 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the 35 desired therapeutic effect, in association with a suitable pharmaceutical excipient.

The active compound is effective over a wide dosage range. For examples, dosages per day normally fall within the range of about 0.01 to about 30 mg/kg of body weight. In the treatment of adult humans, the range of about 0.1 to about 15 mg/kg/day, in single or divided dose, is especially preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several smaller doses for administration throughout the day.

- 72 -

Formulation Example 1

Hard gelatin capsules containing the following ingredients are prepared:

5

	<u>Ingredient</u>	<u>Quantity</u> (mg/capsule)
	Active Ingredient	30.0
10	Starch	305.0
	Magnesium stearate	5.0

15 The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.

Formulation Example 2

A tablet formula is prepared using the ingredients below:

20

	<u>Ingredient</u>	<u>Quantity</u> (mg/tablet)
	Active Ingredient	25.0
25	Cellulose, microcrystalline	200.0
	Colloidal silicon dioxide	10.0
	Stearic acid 5.0	
30		

The components are blended and compressed to form tablets, each weighing 240 mg.

- 73 -

Formulation Example 3

A dry powder inhaler formulation is prepared containing the following components:

	<u>Ingredient</u>	<u>Weight %</u>
5	Active Ingredient	5
10	Lactose	95

10 The active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.

Formulation Example 4

15 Tablets, each containing 30 mg of active ingredient, are prepared as follows:

		<u>Quantity</u> <u>(mg/tablet)</u>
20	<u>Ingredient</u>	
	Active Ingredient	30.0 mg
	Starch	45.0 mg
25	Microcrystalline cellulose	35.0 mg
	Polyvinylpyrrolidone (as 10% solution in water)	4.0 mg
30	Sodium carboxymethyl starch	4.5 mg
	Magnesium stearate	0.5 mg
	Talc	<u>1.0 mg</u>
35	Total	120 mg

The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are 5 then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50-60°C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine 10 to yield tablets each weighing 120 mg.

Formulation Example 5

Capsules, each containing 40 mg of medicament are made 15 as follows:

	<u>Ingredient</u>	<u>Quantity</u> (mg/capsule)
20	Active Ingredient	40.0 mg
	Starch	109.0 mg
	Magnesium stearate	<u>1.0 mg</u>
25	Total	150.0 mg

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.

- 75 -

Formulation Example 6

Suppositories, each containing 25 mg of active ingredient
are made as follows:

5

	<u>Ingredient</u>	<u>Amount</u>
	Active Ingredient	25 mg
	Saturated fatty acid glycerides to	2,000 mg

10

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.

15

Formulation Example 7

Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows:

20

	<u>Ingredient</u>	<u>Amount</u>
	Active Ingredient	50.0 mg
	Xanthan gum	4.0 mg

25

	Sodium carboxymethyl cellulose (11%)	
	Microcrystalline cellulose (89%)	50.0 mg

Sucrose 1.75 g

30

Sodium benzoate 10.0 mg

Flavor and Color q.v.

35 Purified water to 5.0 ml

- 76 -

The medicament, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and 5 color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.

Formulation Example 8

10 Capsules, each containing 15 mg of medicament, are made as follows:

	<u>Ingredient</u>	<u>Quantity</u> (mg/capsule)
15	Active Ingredient	15.0 mg
	Starch	407.0 mg
	Magnesium stearate	<u>3.0 mg</u>
20	Total	425.0 mg

25 The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425 mg quantities.

- 77 -

Formulation Example 9

An intravenous formulation may be prepared as follows:

5

	<u>Ingredient</u>	<u>Quantity</u>
	Active Ingredient	250.0 mg
	Isotonic saline	1000 ml

10

Formulation Example 10

A topical formulation may be prepared as follows:

15

	<u>Ingredient</u>	<u>Quantity</u>
	Active Ingredient	1-10 g
	Emulsifying Wax	30 g
20	Liquid Paraffin	20 g
	White Soft Paraffin	to 100 g

25

The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.

- 78 -

Formulation Example 11

Sublingual or buccal tablets, each containing 10 mg of active ingredient, may be prepared as follows:

5

	<u>Ingredient</u>	<u>Quantity</u> <u>Per Tablet</u>
	Active Ingredient	10.0 mg
10	Glycerol	210.5 mg
	Water	143.0 mg
	Sodium Citrate	4.5 mg
15	Polyvinyl Alcohol	26.5 mg
	Polyvinylpyrrolidone	<u>15.5 mg</u>
	Total	410.0 mg

20

The glycerol, water, sodium citrate, polyvinyl alcohol, and polyvinylpyrrolidone are admixed together by continuous stirring and maintaining the temperature at about 90°C. When the polymers have gone into solution, the solution is cooled to about 50-55°C and the medicament is slowly admixed. The homogenous mixture is poured into forms made of an inert material to produce a drug-containing diffusion matrix having a thickness of about 2-4 mm. This diffusion matrix is then cut to form individual tablets having the appropriate size.

25

Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by

- 79 -

reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly.


5 Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of biological factors to specific anatomical regions of the body, is described in U.S. Patent 5,011,472, issued April 30, 1991, which is herein incorporated by reference.

10 Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs or prodrugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.

- 80 -

We claim:

1. A compound of the formula



5

wherein:

10 R¹ is hydrogen, C₁-C₆ alkyl, or C₂-C₆ alkanoyl;

15 R², R³, R⁴, R⁵, and R⁶ are independently selected from the group consisting of hydrogen, halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylamino, C₁-C₆ alkylthio, amino, and trifluoromethyl;

20

R^a and R^b are each hydrogen or together form an oxo group;

25

R^c and R^d are each hydrogen or together form an oxo group;


Z is a bond or C₁-C₆ alkylene;

n is 0-6; and

25

X is

- 81 -



N-R⁷, CH-NR⁸R⁹, or CH-R¹⁰

5 where R⁷, R⁸, R⁹, and R¹⁰ are independently selected from the group consisting of hydrogen and C₁-C₆ alkyl;

10 or a salt or solvate thereof.

15 2. A compound as claimed in **Claim 1** wherein X, when combined to the heterocyclic ring to which it is attached, forms 4-(piperidin-1-yl)piperidinyl-1-yl, 4-cyclohexylpiperazin-1-yl, 4-phenylpiperazin-1-yl, 4-phenylpiperidin-1-yl, 4-(N,N-dimethylamino)piperidin-1-yl, or 4-(N,N-diethylamino)piperidin-1-yl, or a salt or solvate thereof.

20 3. A compound as claimed in **Claim 2** wherein at least one, but not more than three, of R², R³, R⁴, R⁵, and R⁶ are independently selected from the group consisting of chloro, fluoro, trifluoromethyl, methyl, ethyl, methoxy, ethoxy, methylamine, ethylamine, amino, methylthio, and ethylthio, or a salt or solvate thereof.

25 4. A compound as claimed in **Claim 3** selected from the group consisting of N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide,

- 83 -

diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide,

yl]acetyl]amino]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-5 tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-[3,4,5-tri(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-ethoxybenzyl)-3-(1H-indol-10 3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-15 5-yl)acetyl]amino]propanamide, N-methyl-N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-20 methyl-N-(3,4-dieethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-25 methyl-N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,4,5-tri(2-methoxybenzyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-phenylpiperazin-1-30 5-yl)acetyl]amino]propanamide, N-methyl-N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-

- 85 -

methyl-N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-cyclohexylpiperazin-1-yl)acetyl]amino]propanamide, N-methyl-N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide

yl]acetyl]amino]propanamide, N-methyl-N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, N-methyl-N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, and N-methyl-N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[[[4-(piperidin-1-yl)piperidin-1-yl]acetyl]amino]propanamide, or a salt or solvate thereof.

5. A compound as claimed in **Claim 1** wherein R^a and R^b are taken together to form a carbonyl group, or a salt or solvate thereof.

30 6. A compound as claimed in **Claim 5** selected from the group consisting of N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[[[4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[[[4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-

[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-phenyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-

yl]methyl]carbonyl]propanamide, N-(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-dimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-
5 diethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]propanamide, N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-
2-[(4-methyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-
10 (1H-indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-
indol-3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]propanamide, N-(3,4,5-trimethylbenzyl)-3-(1H-indol-
3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
15 yl]methyl]carbonyl]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-
3-yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-
yl)-2-[(4-methyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-
20 dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-[3,4,5-
tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-methyl)-2,5-
dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-
methoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]propanamide, N-(2-ethoxybenzyl)-3-(1H-indol-3-yl)-2-
25 [(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-
methylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
yl]methyl]carbonyl]propanamide, N-(2-chlorobenzyl)-3-(1H-indol-3-yl)-2-
[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(2-
trifluoromethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-
30 1-yl]methyl]carbonyl]propanamide, N-(2-ethylbenzyl)-3-(1H-indol-3-yl)-2-
[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-
(3,4-dimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-
1-yl]methyl]carbonyl]propanamide, N-(3,4-dimethylbenzyl)-3-(1H-indol-
3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-
35 yl]methyl]carbonyl]propanamide, N-(3,4-diethoxybenzyl)-3-(1H-indol-3-
yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide,


N-(3,4-diethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4-dichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-[3,5-bis(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-trimethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-trimethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-triethoxybenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-triethylbenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, N-(3,4,5-trichlorobenzyl)-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, and N-[3,4,5-tri(trifluoromethyl)benzyl]-3-(1H-indol-3-yl)-2-[(4-benzyl)-2,5-dioxopiperazin-1-yl]methyl]carbonyl]propanamide, or a salt or solvate thereof.

7. A pharmaceutical formulation comprising as an active ingredient a compound as claimed in any one of **Claims 1 to 6**, associated with one or more pharmaceutically acceptable carriers, excipients, or diluents therefor.


8. A compound as claimed in any one of **Claims 1 to 6** for use in treating or preventing a condition associated with an excess of tachykinins.

9. A process for preparing a compound as claimed in any one of **Claims 1 to 6**, which comprises reacting a compound of the formula

- 90 -



with a compound of the formula



5

followed by an optional solvolysis or salination step.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/04571

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/495, 31/445; C07D 401/04, 403/04

US CL :514/253, 316, 323; 544/360, 373; 546/187, 201

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/253, 316, 323; 544/360, 373; 546/187, 201

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,331,089 (Curtis et al) 19 July 1994.	1
A	US, A, 5,360,820 (Hagan et al) 01 November 1994.	1
A,P	US, A, 5,491,140 (BRUNS, Jr. et al) 13 February 1996.	1

Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

18 JUNE 1996

Date of mailing of the international search report

06 AUG 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
CECILIA TSANG
Telephone No. (703) 308-1235